Previous 10 | Next 10 |
JERUSALEM, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced its financial and operating results for the quarter ended J...
JERUSALEM, July 26, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced the formation of its Clinical and Scientific Advisory Board...
Entera Bio ( NASDAQ: ENTX ) appointed its CFO Miranda Toledano as its CEO, effective July 15, replacing Spiros Jamas. In May, Toledano was appointed as CFO, chief business officer and head of Corporate Strategy. Toledano has served as a board member s...
JERUSALEM, July 18, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered peptides and therapeutic proteins, announced today the execution of the following key milestones: The U.S. Food and Drug Administration (FDA) has granted En...
BOSTON and JERUSALEM, June 17, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered peptides and therapeutic proteins, today announced that Dr. Phillip Schwartz, the Company’s President of Research & Development and Founder, wil...
Entera Bio Ltd. (ENTX) Q1 2022 Earnings Conference Call May 17, 2022 08:00 ET Company Participants Spiros Jamas - Chief Executive Officer Miranda Toledano - Chief Business Officer, Chief Financial Officer & Head of Strategy Arthur Santora - Chief Medical Officer Conference Call Participan...
Entera Bio (NASDAQ:ENTX) has appointed Miranda Toledano as Chief Business Officer, Chief Financial Officer, and Head of Corporate Strategy, effective immediately. Toledano is a biotechnology industry veteran with 25 years of C-level leadership, principal investment and capital markets experie...
BOSTON and JERUSALEM, May 16, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the appointment of Miranda Toledano, one of Entera’s existing board members, as Chief Business Officer, ...
Entera Bio press release (NASDAQ:ENTX): Q1 GAAP EPS of -$0.13 beats by $0.05. Revenue of $0.07M (-56.3% Y/Y) misses by $0.02M. As of March 31, 2022, Entera had cash and cash equivalents of $20.1 million, compared to $24.9 million as of December 31, 2021. Entera expects that the current cash i...
Registrational study design for lead clinical asset, EB613, as the first oral PTH anabolic to treat post-menopausal women at high risk of osteoporosis, is underway Company reschedules conference call and webcast to Wednesday, May 18 at 8:00 AM EDT BOSTON and JERUSALEM, May 12, 2...
News, Short Squeeze, Breakout and More Instantly...